Hideaki Nitta

Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.

Recently, elevated peripheral blood monocyte counts at diagnosis have been shown to be an independent marker associated with poor prognosis in patients with both non-Hodgkin and Hodgkin lymphoma. In this study, we retrospectively analyzed the data from a total of 550 patients with diffuse large B-cell lymphoma and evaluated the relationship between central nervous system relapse and absolute monocyte counts at diagnosis. Twenty-six patients developed central nervous system relapse. The central nervous system relapse-free survival rate was significantly lower in patients with the absolute monocyte counts ≥0.51×109/L (87.8% versus 96.4%; P<0.001). This association was independently significant after adjusting for other significant factors, including systemic relapse as a time-dependent covariate by multivariate analysis (hazard ratio 2.46; 95% confidence intervals 1.05–5.75; P=0.039). These results suggest that the absolute monocyte count at diagnosis is an independent significant risk factor for central nervous system relapse in patients with diffuse large B-cell lymphoma.

Expansion of CD8+/perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia

Paris), E Cheuret, I Glorieux, N Montjaux, S Lebon, JY le Tallec (Toulouse), Y Lakhdari, E Saliba (Tours), C Mignot, ML Moutard (Trousseau, Paris), N Benbrik, D Soupre (Vannes), A Cailho, C Coudy (Versailles), C Ringenbach (Villefranche sur Sâone), N Blanc, MJ Boivin, F Guillot (Villeneuve Saint-Georges) as local clinicians. D Allard, L Hertz-Pannier, B Husson (radiology), MN Varlet (obstetric), B Tardy (haemostasis).

Expansion of CD8+/perforin+T-cells predicts response to ciclosporin A therapy in patients with erythroid hypoplasia/aplasia

Fogarty, P.F. (2009) Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematology/Oncology Clinics of North America, 23, 1213–1221. Kuter, D.J., Bussel, J.B., Lyons, R.M., Pullarkat, V., Gernsheimer, T.B., Senecal, F.M., Aledort, L.M., George, J.N., Kessler, C.M., Sanz, M.A., Liebman, H.A., Slovick, F.T., de Wolf, J.T., Bourgeois, E., Guthrie, Jr, T.H., Newland, A., Wasser, J.S., Hamburg, S.I., Grande, C., Lefre‘re, F., Lichtin, A.E., Tarantino, M.D., Terebelo, H.R., Viallard, J.F., Cuevas, F.J., Go, R.S., Henry, D. H., Redner, R.L., Rice, L., Schipperus, M.R., Guo, D.M. & Nichol, J.L. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 37, 95–403. Severinsen, M.T., Engebjerg, M.C., Farkas, D.K., Jensen, A.Ø., Nørgaard, M., Zhao, S. & Sørensen, H.T. (2010) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. British Journal of Haematology, 152, 360–362. Stasi, R. (2011) Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfusion, 9, 262–273. Tagariello, G., Sartori, R., Radossi, P., Maschio, N., Risato, R. & Stasi, R. (2011) Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment. British Journal of Haematology. Doi: 10.1111/j.1365-2141.2011.08950.x. [Epub ahead of print].

Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement

Baumann, U., Fern andez-S aiz, V., Rudelius, M., Lemeer, S., Rad, R., Knorn, A.M., Slawska, J., Engel, K., Jeremias, I., Li, Z., Tomiatti, V., Illert, A.L., Targosz, B.S., Braun, M., Perner, S., Leitges, M., Klapper, W., Dreyling, M., Miething, C., Lenz, G., Rosenwald, A., Peschel, C., Keller, U., Kuster, B. & Bassermann, F. (2014) Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nature Medicine, 20, 1401–1409. Fadeel, B. & Grzybowska, E. (2009) HAX-1: a multifunctional protein with emerging roles in human disease. Biochimica et Biophysica Acta, 1790, 1139–1148. Han, J., Goldstein, L.A., Hou, W., Froelich, C.J., Watkins, S.C. & Rabinowich, H. (2010) Deregulation of mitochondrial membrane potential by mitochondrial insertion of granzyme B and direct Hax-1 cleavage. Journal of Biological Chemistry, 285, 22461–22472. Jitkaew, S., Trebinska, A., Grzybowska, E., Carlsson, G., Nordstr€ om, A., Lehti€ o, J., Fr€ ojmark, A.S., Dahl, N. & Fadeel, B. (2009) N-tosyl-Lphenylalanine chloromethyl ketone induces caspase-dependent apoptosis in transformed human B cell lines with transcriptional downregulation of anti-apoptotic HS1-associated protein X-1. Journal of Biological Chemistry, 284, 27827–27837. Kilpinen, S., Autio, R., Ojala, K., Iljin, K., Bucher, E., Sara, H., Pisto, T., Saarela, M., Skotheim, R.I., Bj€ orkman, M., Mpindi, J.P., Haapa-Paananen, S., Vainio, P., Edgren, H., Wolf, M., Astola, J., Nees, M., Hautaniemi, S. & Kallioniemi, O. (2008) Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biology, 9, R139. Klein, C., Grudzien, M., Appaswamy, G., Germeshausen, M., Sandrock, I., Sch€affer, A.A., Rathinam, C., Boztug, K., Schwinzer, B., Rezaei, N., Bohn, G., Melin, M., Carlsson, G., Fadeel, B., Dahl, N., Palmblad, J., Henter, J.I., Zeidler, C., Grimbacher, B. & Welte, K. (2007) HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nature Genetics, 39, 86–92. Kwiecinska, A., Ottosson-Wadlund, A., Ceder, R., Grafstr€ om, R.C., Bj€ orck, E., Nordenskj€ old, M., Porwit, A. & Fadeel, B. (2011) HAX-1 expression in human B lymphoma. Leukemia, 25, 868–872. Peckl-Schmid, D., Wolkerstorfer, S., K€ onigsberger, S., Achatz-Straussberger, G., Feichtner, S., Schwaiger, E., Zaborsky, N., Huemer, M., Gratz, I.K., Schibli, R., Lamers, M., Crameri, R., Moser, K., Luger, E.O. & Achatz, G. (2010) HAX1 deficiency: impact on lymphopoiesis and B-cell development. European Journal of Immunology, 40, 3161–3172. Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., Jagannath, S., Sezer, O., Kristinsson, S.Y., Caers, J., Usmani, S.Z., Lahuerta, J.J., Johnsen, H.E., Beksac, M., Cavo, M., Goldschmidt, H., Terpos, E., Kyle, R.A., Anderson, K.C., Durie, B.G. & Miguel, J.F. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15, e538–e548. Ramsay, A.G., Keppler, M.D., Jazayeri, M., Thomas, G.J., Parsons, M., Violette, S., Weinreb, P., Hart, I.R. & Marshall, J.F. (2007) HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin avb6. Cancer Research, 67, 5275–5284.

Study of patient risk factors for febrile neutropenia in non-Hodgkin lymphoma receiving R-CHOP regimen: STOP FN single institution analysis in Japan.

e21605Background: Cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP) is standard therapy for patients (pts) with CD20 positive non-Hodgkin lymphomas (CD20+NHLs). America...